For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
Investor's Business Daily on MSN
Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot
Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved ...
People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...
Zacks Investment Research on MSN
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
Gilead Sciences, Inc. GILD posted better-than-expected third-quarter 2025 results and lifted the lower end of its product ...
Return to shareholders -- $1.4 billion was returned to shareholders as of fiscal Q3 2025 through dividends and share repurchases. Anticipated step-up in expenses -- Research and development, as well ...
Dzidzai is one of 25 Community Adolescent Treatment Supporters (CATS) trained by the National Aids Council (NAC) and the ...
More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...
Wall Street expected sales of Yeztugo, which has an annual U.S. list price of about $28,000, at $37.5 million, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback